1248517-38-5

Basic information

• Product Name: 4-(azidomethyl)-2-bromo-1-methoxybenzene
• Synonyms: 4-(azidomethyl)-2-bromo-1-methoxybenzene
• CAS NO: 1248517-38-5
• Molecular Weight: 242.075
• Mol File: 1248517-38-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(azidomethyl)-2-bromo-1-methoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(azidomethyl)-2-bromo-1-methoxybenzene(1248517-38-5)
• EPA Substance Registry System: 4-(azidomethyl)-2-bromo-1-methoxybenzene(1248517-38-5)

Safety Data

• Hazardous Substances Data: 1248517-38-5(Hazardous Substances Data)

Upstream product

• 824-94-2 p-methoxybenzyl chloride 
• 38493-59-3 (3-bromo-4-methoxy-phenyl)-methanol 
• 701-94-0 3-bromo-4-methoxybenzyl chloride 

Relevant articles and documents

Click-based synthesis of bromotyrosine alkaloid analogs as potential anti-biofilm leads for SAR studies

A library of triazole-based analogs of bromotyramine alkaloids such as verongamines, hemibastadins, pseudoceramine D and clavatidine E was designed in order to identify promising leads that may help in the control of bacterial biofilms. Twenty-three compounds were screened for their biofilm inhibitory activity against three strains of Gram-negative bacteria. SAR studies revealed that hemibastadins analogs were the most active compounds which act as inhibitors of biofilm development (EC50 8.8-29 μM) without effect on bacterial growth even at high concentrations (100 μM).

1,2,3-Triazole analogs of combretastatin A-4 as potential microtubule-binding agents

A series of cis-restricted 1,4- and 1,5-disubstituted 1,2,3-triazole analogs of combretastatin A-4 (1) have been prepared. Cytotoxicity and tubulin inhibition studies showed that 2-methoxy-5-((5-(3,4,5-trimethoxyphenyl)-1H-1,2, 3-triazol-1-yl)methyl)aniline (5e) and 2-methoxy-5-(1-(3,4,5-trimethoxybenzyl)- 1H-1,2,3-triazol-5-yl)aniline (6e) were two of the most active compounds. Molecular modeling studies revealed that the N-2 and N-3 atoms in the triazole rings in 5e and 6e did not form hydrogen bonds with the amino acids in the anticipated pharmacophore.